文献速递精神分裂症与精神病性障碍儿童青少年精神

神经连接蛋白在孤独症与精神分裂症中的作用:患者突变、小鼠模型与未来方向综述

Neurexins in autism and schizophrenia-a review of patient mutations, mouse models and potential future directions.
PubMed 文献 · Mol Psychiatry · 2020-11-15

本综述汇总了在孤独症谱系障碍(ASD)和精神分裂症(SCZ)患者中反复发现的神经连接蛋白家族(NRXN1、NRXN2、NRXN3)突变,以及现有小鼠模型研究。作者指出,基于完全功能缺失(LOF)的传统遗传学方法可能不足以揭示这些人类突变的作用,并提出了未来研究方向。

要点

  • NRXN1、NRXN2、NRXN3 突变在 ASD 与 SCZ 患者中反复被识别。
  • 传统完全 LOF 小鼠模型可能无法充分揭示人类突变致病机制。
  • 人类变异可能经单倍剂量不足或异常异构体获得功能(GOF)等复杂机制起作用。

核心结论

  • 神经连接蛋白家族(NRXN1、NRXN2、NRXN3)突变与 ASD 和 SCZ 相关,但其影响神经连接蛋白功能并易感这些神经发育障碍的机制仍不清楚。
  • 传统基于完全功能缺失(LOF)的遗传学方法可能不足以揭示这些人类突变的作用。

研究设计与样本

  • 综述类:汇总人类研究中识别的神经连接蛋白变异及当前使用的小鼠模型相关文献。

主要发现

  • NRXN1、NRXN2、NRXN3 突变在 ASD 和 SCZ 患者中被反复发现。
  • 这些基因转录组非常复杂,所有异构体完全 LOF 可能不是患者毒性的原因,尤其有证据提示致病变异通过单倍剂量不足起作用。
  • 人类 DNA 变异可能不都导致 LOF,而可能导致复杂的转录组改变,包括产生起获得功能(GOF)作用的异常异构体。
  • 转录组复杂性使这些基因在传统定点诱变操作时易发生遗传补偿,且可能因模型不同而产生异质和冲突的表型。

临床怎么用

  • 解读神经连接蛋白变异时需考虑其可能经单倍剂量不足或异常异构体获得功能等复杂机制起作用,而非仅完全 LOF。
  • 使用小鼠模型研究这些人类变异时需警惕遗传补偿及模型间表型异质性问题。

局限性

  • 人类变异在体内的潜在致病作用仍不明确。
  • 传统完全 LOF 小鼠模型可能不足以揭示人类突变的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in the family of neurexins (NRXN1, NRXN2 and NRXN3) have been repeatedly identified in patients with autism spectrum disorder (ASD) and schizophrenia (SCZ). However, it remains unclear how these DNA variants affect neurexin functions and thereby predispose to these neurodevelopmental disorders. Understanding both the wild-type and pathologic roles of these genes in the brain could help unveil biological mechanisms underlying mental disorders. In this regard, numerous studies have focused on generating relevant loss-of-function (LOF) mammalian models. Although this has increased our knowledge about their normal functions, the potential pathologic role(s) of these human variants remains elusive. Indeed, after reviewing the literature, it seems apparent that a traditional LOF-genetic approach based on complete LOF might not be sufficient to unveil the role of these human mutations. First, these genes present a very complex transcriptome and total-LOF of all isoforms may not be the cause of toxicity in patients, particularly given evidence that causative variants act through haploinsufficiency. Moreover, human DNA variants may not all lead to LOF but potentially to intricate transcriptome changes that could also include the generation of aberrant isoforms acting as a gain-of-function (GOF). Furthermore, their transcriptomic complexity most likely renders them prone to genetic compensation when one tries to manipulate them using traditional site-directed mutagenesis approaches, and this could act differently from model to model leading to heterogeneous and conflicting phenotypes. This review compiles the relevant literature on variants identified in human studies and on the mouse models currently deployed, and offers suggestions for future research.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Tromp A, Mowry B, Giacomotto J, et al. Neurexins in autism and schizophrenia-a review of patient mutations, mouse models and potential future directions. Mol Psychiatry. 2020. PMID: 33191396. doi:10.1038/s41380-020-00944-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。